BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood 2017;130:1181-8. [PMID: 28768626 DOI: 10.1182/blood-2017-04-636431] [Cited by in Crossref: 97] [Cited by in F6Publishing: 83] [Article Influence: 19.4] [Reference Citation Analysis]
Number Citing Articles
1 Legan ER, Li R. FAM-tastic phospho-regulation of von Willebrand factor activity. J Thromb Haemost 2019;17:863-5. [PMID: 30985992 DOI: 10.1111/jth.14448] [Reference Citation Analysis]
2 Kong DQ, Yin J, Yu ZQ, Zhou SY, Li J, Han Y, Wang ZY, Ruan CG. [Thrombotic thrombocytopenic purpura complicated with acute erythropoiesis dysfunction: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi 2019;40:141-3. [PMID: 30831630 DOI: 10.3760/cma.j.issn.0253-2727.2019.02.009] [Reference Citation Analysis]
3 Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, López JA, Lindner JR. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood 2019;133:1597-606. [PMID: 30692122 DOI: 10.1182/blood-2018-10-881557] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
4 Hrdinová J, D'Angelo S, Graça NAG, Ercig B, Vanhoorelbeke K, Veyradier A, Voorberg J, Coppo P. Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Haematologica 2018;103:1099-109. [PMID: 29674502 DOI: 10.3324/haematol.2016.151407] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
5 Bitzan M, Hammad RM, Bonnefoy A, Al Dhaheri WS, Vézina C, Rivard GÉ. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. Pediatr Nephrol 2018;33:1437-42. [PMID: 29728803 DOI: 10.1007/s00467-018-3957-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Alavi P, Rathod AM, Jahroudi N. Age-Associated Increase in Thrombogenicity and Its Correlation with von Willebrand Factor. J Clin Med 2021;10:4190. [PMID: 34575297 DOI: 10.3390/jcm10184190] [Reference Citation Analysis]
7 Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood 2018;132:141-7. [PMID: 29866815 DOI: 10.1182/blood-2018-02-769000] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 16.0] [Reference Citation Analysis]
8 Cracowski J, Roustit M. Human Skin Microcirculation. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 1105-54. [DOI: 10.1002/cphy.c190008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
9 Galstyan GM, Klebanova EE. [Diagnosis of thrombotic thrombocytopenic purpura]. Ter Arkh 2020;92:207-17. [PMID: 33720596 DOI: 10.26442/00403660.2020.12.200508] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kubo M, Sakai K, Yoshii Y, Hayakawa M, Matsumoto M. Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan. Int J Hematol 2020;112:764-72. [PMID: 32856231 DOI: 10.1007/s12185-020-02974-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun. 2018;93:24-36. [PMID: 30077425 DOI: 10.1016/j.jaut.2018.07.018] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 26.0] [Reference Citation Analysis]
12 Long B, Bridwell RE, Manchanda S, Gottlieb M. Evaluation and Management of Thrombotic Thrombocytopenic Purpura in the Emergency Department. J Emerg Med 2021;61:674-82. [PMID: 34518045 DOI: 10.1016/j.jemermed.2021.07.045] [Reference Citation Analysis]
13 Meng P, Wu L, Lin Q, Zhang Y. Zebrafish for thrombocytopoiesis- and hemostasis-related researches and disorders. Blood Sci 2020;2:44-9. [PMID: 35402814 DOI: 10.1097/BS9.0000000000000043] [Reference Citation Analysis]
14 Dai YL, Tang X, Chen HB, Peng QY, Guo X, Gao J. Hereditary Thrombotic Thrombocytopenic Purpura in a Chinese Boy With a Novel Compound Heterozygous Mutation of the ADAMTS13 Gene. Front Pediatr 2020;8:554. [PMID: 33014938 DOI: 10.3389/fped.2020.00554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Portuguese AJ, Gleber C, Passero FC, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research 2019;85:106195. [DOI: 10.1016/j.leukres.2019.106195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tripodi A, Rossi SC, Clerici M, Merati G, Scalambrino E, Mancini I, Baronciani L, Boscarino M, Monzani V, Peyvandi F. Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. Clin Chem Lab Med 2021;59:1699-708. [PMID: 34192831 DOI: 10.1515/cclm-2021-0538] [Reference Citation Analysis]
17 Goh CY, Patmore S, Smolenski A, Howard J, Evans S, O'Sullivan J, McCann A. The role of von Willebrand factor in breast cancer metastasis. Transl Oncol 2021;14:101033. [PMID: 33571850 DOI: 10.1016/j.tranon.2021.101033] [Reference Citation Analysis]
18 Chang JC. Disseminated intravascular coagulation: new identity as endotheliopathy-associated vascular microthrombotic disease based on in vivo hemostasis and endothelial molecular pathogenesis. Thromb J 2020;18:25. [PMID: 33061857 DOI: 10.1186/s12959-020-00231-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Chapin J. Von Willebrand disease in the elderly: clinical perspectives. Clin Interv Aging 2018;13:1531-41. [PMID: 30214173 DOI: 10.2147/CIA.S136931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
20 Sakai K, Kuwana M, Tanaka H, Hosomichi K, Hasegawa A, Uyama H, Nishio K, Omae T, Hishizawa M, Matsui M, Iwato K, Okamoto A, Okuhiro K, Yamashita Y, Itoh M, Kumekawa H, Takezako N, Kawano N, Matsukawa T, Sano H, Ohshiro K, Hayashi K, Ueda Y, Mushino T, Ogawa Y, Yamada Y, Murata M, Matsumoto M. HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR. Blood 2020;135:2413-9. [DOI: 10.1182/blood.2020005395] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
21 Liu X, Gao W, Wu Y. Two-fold interpenetrated Cd(II) compound: Photocatalytic property and application values on persistent thrombocytopenic purpura. Journal of Molecular Structure 2022;1247:131328. [DOI: 10.1016/j.molstruc.2021.131328] [Reference Citation Analysis]
22 Arcudi S, Ferrari B, Pontiggia S, Tufano A, Artoni A, Mancini I, Peyvandi F. Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series. J Thromb Haemost 2019;17:492-8. [PMID: 30629316 DOI: 10.1111/jth.14381] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Piedrafita A, Ribes D, Cointault O, Chauveau D, Faguer S, Huart A. Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice. Transfus Apher Sci 2020;59:102990. [PMID: 33272850 DOI: 10.1016/j.transci.2020.102990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Patella F, Vendramin C, Charles O, Scully MA, Cutler DF. Shrinking Weibel-Palade bodies prevents high platelet recruitment in assays using thrombotic thrombocytopenic purpura plasma. Res Pract Thromb Haemost 2021;5:e12626. [PMID: 34934893 DOI: 10.1002/rth2.12626] [Reference Citation Analysis]
25 Alshamam MS, Sumbly V, Khan S, Nso N, Rizzo V. Acquired Thrombotic Thrombocytopenic Purpura in a Newly Diagnosed HIV Patient: A Case Report and Literature Review. Cureus 2021;13:e15967. [PMID: 34336459 DOI: 10.7759/cureus.15967] [Reference Citation Analysis]
26 Umapathi KK, Thavamani A, Puliyel M. Predictors of In-Hospital Mortality in Thrombotic Thrombocytopenic Purpura in Children in the United States: A Population Analysis. J Pediatr Hematol Oncol 2020;42:e340-4. [PMID: 32011563 DOI: 10.1097/MPH.0000000000001725] [Reference Citation Analysis]
27 Randi AM, Smith KE, Castaman G. von Willebrand factor regulation of blood vessel formation. Blood. 2018;132:132-140. [PMID: 29866817 DOI: 10.1182/blood-2018-01-769018] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
28 Szóstek-Mioduchowska A, Kordowitzki P. Shedding Light on the Possible Link between ADAMTS13 and Vaccine-Induced Thrombotic Thrombocytopenia. Cells 2021;10:2785. [PMID: 34685765 DOI: 10.3390/cells10102785] [Reference Citation Analysis]
29 Buetler VA, Agbariah N, Schild DP, Liechti FD, Wieland A, Andina N, Hammann F, Kremer Hovinga JA. Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature. Front Med (Lausanne) 2022;9:890661. [PMID: 35655852 DOI: 10.3389/fmed.2022.890661] [Reference Citation Analysis]
30 Li YT, Du HZ, Wang CY, Zhu TN, Pan BJ, Zhang L. Cholangiocarcinoma presenting with acquired thrombotic thrombocytopenic purpura confirmed by positive autoantibodies of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13. Chin Med J (Engl) 2020;133:1495-6. [PMID: 32187046 DOI: 10.1097/CM9.0000000000000727] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Aiempanakit K, Apinantriyo B. Thrombotic thrombocytopenic purpura and hemophagocytic lymphohistiocytosis in an elderly man: A case report. Medicine (Baltimore) 2018;97:e13025. [PMID: 30383662 DOI: 10.1097/MD.0000000000013025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Reddy MS, Hofmann S, Shen YM, Nagalla S, Rambally S, Usmani A, Sarode R. Comparison of low fixed dose versus standard-dose rituximab to treat thrombotic thrombocytopenic purpura in the acute phase and preemptively during remission. Transfus Apher Sci 2020;59:102885. [PMID: 32739120 DOI: 10.1016/j.transci.2020.102885] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Le Clef Q, Menter T, Tzankov A. Our approach to bone marrow biopsies in cytopenia. Pathol Res Pract 2019;215:152447. [PMID: 31101575 DOI: 10.1016/j.prp.2019.152447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Adili R, Holinstat M. Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura. Arterioscler Thromb Vasc Biol 2019;39:1817-30. [PMID: 31340669 DOI: 10.1161/ATVBAHA.119.312848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
35 Kremer Hovinga JA, Braschler TR, Buchkremer F, Farese S, Hengartner H, Lovey PY, Largiadèr CR, Mansouri Taleghani B, Tarasco E. Insights from the Hereditary Thrombotic Thrombocytopenic Purpura Registry: Discussion of Key Findings Based on Individual Cases from Switzerland. Hamostaseologie 2020;40:S5-S14. [PMID: 33187004 DOI: 10.1055/a-1282-2264] [Reference Citation Analysis]
36 Ali Z, Zafar MU, Wolfe Z, Akbar F, Lash B. Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature. Cureus 2020;12:e11246. [PMID: 33274128 DOI: 10.7759/cureus.11246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Chou SC, Lin DT, Lin CY, Huang YC, Hsieh HN, Shen MC. First reported case of congenital thrombotic thrombocytopenic purpura in Taiwan with novel mutation of ADAMTS13 gene. Int J Hematol 2021;113:760-4. [PMID: 33387295 DOI: 10.1007/s12185-020-03068-5] [Reference Citation Analysis]
38 Sarode R. Recombinant ADAMTS-13: goodbye, allergic reactions! Blood 2017;130:2045-6. [DOI: 10.1182/blood-2017-09-807164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
39 Kucukyurt S, Eskazan AE. Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes. J Blood Med 2020;11:319-26. [PMID: 33061729 DOI: 10.2147/JBM.S205630] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura. Expert Rev Hematol 2020;13:1153-64. [PMID: 32876503 DOI: 10.1080/17474086.2020.1819230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Miyata T. Autoantibody-resistant ADAMTS13 variant. Blood 2021;137:2575-6. [PMID: 33983424 DOI: 10.1182/blood.2021011147] [Reference Citation Analysis]
42 Sakai K, Wada H, Nakatsuka Y, Kubo M, Hayakawa M, Matsumoto M. Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura. J Intensive Care Med 2021;36:436-42. [PMID: 31964209 DOI: 10.1177/0885066619899637] [Reference Citation Analysis]
43 López-Lera A, Corvillo F, Nozal P, Regueiro JR, Sánchez-Corral P, López-Trascasa M. Complement as a diagnostic tool in immunopathology. Semin Cell Dev Biol 2019;85:86-97. [PMID: 29292221 DOI: 10.1016/j.semcdb.2017.12.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
44 Di Micco P, Camporese G, Cardillo G, Lodigiani C, Carannante N, Annunziata A, Fiorentino G, Russo V, Imbalzano E. Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. Medicina (Kaunas) 2021;57:997. [PMID: 34684034 DOI: 10.3390/medicina57100997] [Reference Citation Analysis]
45 Yu S, Liu W, Fang J, Shi X, Wu J, Fang Y, Lin J. AFM Imaging Reveals Multiple Conformational States of ADAMTS13. J Biol Eng 2019;13:9. [PMID: 30679946 DOI: 10.1186/s13036-018-0102-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
46 Pascual C, Nieto JM, Fidalgo T, Seguí IG, Díaz-Ricart M, Docampo MF, Del Rio J, Salinas R. Multicentric evaluation of the new HemosIL Acustar® chemiluminescence ADAMTS13 activity assay. Int J Lab Hematol 2021;43:485-93. [PMID: 33264480 DOI: 10.1111/ijlh.13414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Veyradier A. A new drug for an old concept: aptamer to von Willebrand factor for prevention of arterial and microvascular thrombosis. Haematologica 2020;105:2512-5. [PMID: 33131243 DOI: 10.3324/haematol.2020.261081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Sun S, Urbanus RT, ten Cate H, de Groot PG, de Laat B, Heemskerk JWM, Roest M. Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia. Cells 2021;10:3386. [DOI: 10.3390/cells10123386] [Reference Citation Analysis]
49 Shields MD, Skelton WP 4th, Laber DA, Verbosky M, Ashraf N. A Novel Case of Leflunomide-Induced Thrombotic Thrombocytopenic Purpura. J Hematol 2021;10:139-42. [PMID: 34267852 DOI: 10.14740/jh837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Lämmle B. Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies. Hamostaseologie 2020;40:414-9. [DOI: 10.1055/a-1191-7198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Gómez-de León A, Villela-martínez LM, Yáñez-reyes JM, Gómez-almaguer D. Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents. Expert Review of Hematology 2020;13:461-70. [DOI: 10.1080/17474086.2020.1750361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Matsumoto H, Takeba J, Umakoshi K, Kikuchi S, Ohshita M, Annen S, Moriyama N, Nakabayashi Y, Sato N, Aibiki M. ADAMTS13 activity decreases in the early phase of trauma associated with coagulopathy and systemic inflammation: a prospective observational study. Thromb J 2021;19:17. [PMID: 33712048 DOI: 10.1186/s12959-021-00270-1] [Reference Citation Analysis]
53 Kaplan A, Sevcik J, Kiss JE. Low titer A plasma in three AB patients for therapeutic plasma exchange. J Clin Apher 2019;34:7-12. [DOI: 10.1002/jca.21656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Pluthero FG, Kahr WHA. The Birth and Death of Platelets in Health and Disease. Physiology (Bethesda) 2018;33:225-34. [PMID: 29638183 DOI: 10.1152/physiol.00005.2018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
55 Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost 2020;18:479-84. [PMID: 31691462 DOI: 10.1111/jth.14679] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
56 Kremer Hovinga JA, Heeb SR, Skowronska M, Schaller M. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. J Thromb Haemost 2018;16:618-29. [DOI: 10.1111/jth.13956] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
57 Lin Q, Fan L, Huang H, Zeng F, Fu D, Wei S. Combination of Fresh Frozen Plasma and Cryosupernatant Plasma for Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. Biomed Res Int 2019;2019:1756109. [PMID: 30834255 DOI: 10.1155/2019/1756109] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Decker P, Moulinet T, Revuz S, Perez P, Jaussaud R. Thrombotic Thrombocytopenic Purpura Without Schistocytes: Beware of Misdiagnosis. Neurol Clin Pract 2021;11:e798-800. [PMID: 34840915 DOI: 10.1212/CPJ.0000000000001067] [Reference Citation Analysis]
59 Yu K, Yan M. A Case of Thrombotic Thrombocytopenic Purpura without Pathognomonic Schistocytes. Clin Pract 2021;11:223-7. [PMID: 33924287 DOI: 10.3390/clinpract11020033] [Reference Citation Analysis]
60 Galstyan GM, Maschan AA, Klebanova EE, Kalinina II. Treatment of thrombotic thrombocytopenic purpura. Terapevticheskii arkhiv 2021;93:736-45. [DOI: 10.26442/00403660.2021.06.200894] [Reference Citation Analysis]
61 Peedin AR, Park YA, Mazepa MA, Rollins-raval MA, Brecher ME, Raval JS. Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange: Schistocyte Persistence in TTP. Ther Apher Dial 2018;22:662-5. [DOI: 10.1111/1744-9987.12713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Browning S, Bahar B, Lee AI, Gorshein E. Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a 'subclinical' TTP state. Hematology 2020;25:473-7. [PMID: 33269995 DOI: 10.1080/16078454.2020.1848973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Bécel G, Faict S, Picod A, Bouzid R, Veyradier A, Coppo P. Thrombotic Thrombocytopenic Purpura: When Basic Science Meets Clinical Research. Hamostaseologie 2021;41:283-93. [PMID: 33607665 DOI: 10.1055/a-1332-3066] [Reference Citation Analysis]
64 Tsuda M, Shiratsuchi M, Nakashima Y, Ikeda M, Muta H, Narazaki T, Masuda T, Kimura D, Takamatsu A, Matsumoto M, Fujimura Y, Kokame K, Matsushima T, Ogawa Y. Upshaw-Schulman syndrome diagnosed during pregnancy complicated by reversible cerebral vasoconstriction syndrome. Transfusion and Apheresis Science 2018;57:790-2. [DOI: 10.1016/j.transci.2018.10.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Xu J, Guan J, Li Q, Qian J, Wang Y, Huang Y, Chen B, Yang Y. Sudden coma at the onset of severe refractory thrombotic thrombocytopenic purpura with successful treatment. Transfus Apher Sci 2021;:103225. [PMID: 34384720 DOI: 10.1016/j.transci.2021.103225] [Reference Citation Analysis]
66 Kayashima M, Sakai K, Harada K, Kanetake J, Kubo M, Hamada E, Hayakawa M, Hatakeyama K, Matsumoto M. Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. Int J Hematol 2021;114:415-23. [PMID: 34292506 DOI: 10.1007/s12185-021-03197-5] [Reference Citation Analysis]
67 Jestin M, Benhamou Y, Schelpe AS, Roose E, Provôt F, Galicier L, Hié M, Presne C, Poullin P, Wynckel A, Saheb S, Deligny C, Servais A, Girault S, Delmas Y, Kanouni T, Lautrette A, Chauveau D, Mousson C, Perez P, Halimi JM, Charvet-Rumpler A, Hamidou M, Cathébras P, Vanhoorelbeke K, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Center. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood 2018;132:2143-53. [PMID: 30201758 DOI: 10.1182/blood-2018-04-840090] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
68 Tarasco E, Bütikofer L, Friedman KD, George JN, Hrachovinova I, Knöbl PN, Matsumoto M, von Krogh AS, Aebi-Huber I, Cermakova Z, Górska-Kosicka M, Jalowiec KA, Largiadèr CR, Prohászka Z, Sinkovits G, Windyga J, Lämmle B, Kremer Hovinga JA. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood 2021;137:3563-75. [PMID: 33649760 DOI: 10.1182/blood.2020009801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
69 Nguyen T, Radhakrishnan SM, Radhakrishnan SJ, Johnson DH. Near-complete vision recovery from bilateral serous retinal detachment associated with thrombotic thrombocytopenic purpura. BMJ Case Rep 2022;15:e244030. [PMID: 35131768 DOI: 10.1136/bcr-2021-244030] [Reference Citation Analysis]
70 Gallan AJ, Chang A. A New Paradigm for Renal Thrombotic Microangiopathy. Semin Diagn Pathol 2020;37:121-6. [PMID: 32085935 DOI: 10.1053/j.semdp.2020.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
71 Hicks SM, Lee CSM, Ali SA, Choi PY, Gardiner EE. The molecular basis of immune-based platelet disorders. Clin Sci (Lond) 2020;134:2807-22. [PMID: 33140828 DOI: 10.1042/CS20191101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Carden MA, Gaddh M, Hoskote A, Brown M, Merrill V, Stowell SR, Chandrakasan S, Antun A, Kudchadkar R, Kotanchiyev S, Jaye DL, Bodó I. Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx. Blood Adv 2020;4:477-81. [PMID: 32027742 DOI: 10.1182/bloodadvances.2019001148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Sakai K, Fujimura Y, Nagata Y, Higasa S, Moriyama M, Isonishi A, Konno M, Kajiwara M, Ogawa Y, Kaburagi S, Hara T, Kokame K, Miyata T, Hatakeyama K, Matsumoto M. Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2929-41. [PMID: 33433066 DOI: 10.1111/jth.15064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Cilla N, Dallemagne J, Vanhove M, Stordeur P, Motte S, De Wilde V. Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab. J Hematol 2020;9:84-8. [PMID: 32855757 DOI: 10.14740/jh614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Sakai K, Fujimura Y, Miyata T, Isonishi A, Kokame K, Matsumoto M. Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort. Br J Haematol 2021;194:444-52. [PMID: 34046888 DOI: 10.1111/bjh.17560] [Reference Citation Analysis]
76 Koneczny I. Update on IgG4-mediated autoimmune diseases: New insights and new family members. Autoimmun Rev 2020;19:102646. [PMID: 32801046 DOI: 10.1016/j.autrev.2020.102646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
77 Lemiale V, Valade S, Mariotte E. Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions. Ther Clin Risk Manag 2021;17:577-87. [PMID: 34113115 DOI: 10.2147/TCRM.S205632] [Reference Citation Analysis]
78 Noutsos T, Currie BJ, Isoardi KZ, Brown SGA, Isbister GK. Snakebite-associated thrombotic microangiopathy: an Australian prospective cohort study [ASP30]. Clin Toxicol (Phila) 2021;:1-9. [PMID: 34328386 DOI: 10.1080/15563650.2021.1948559] [Reference Citation Analysis]
79 le Besnerais M, Veyradier A, Benhamou Y, Coppo P. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opin Biol Ther 2019;19:1127-34. [PMID: 31359806 DOI: 10.1080/14712598.2019.1650908] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
80 Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, Novembrino C, Boscolo Anzoletti M, De Zan V, Pagliari MT, Gualtierotti R, Aliberti S, Panigada M, Grasselli G, Blasi F, Peyvandi F. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost 2021;19:513-21. [PMID: 33230904 DOI: 10.1111/jth.15191] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
81 Kamal A, Hafez Youssef A, Refaat Mansour A. Acute Hepatitis Caused by Genotype 4 HCV Presenting with Microangiopathic Hemolytic Anemia. ACG Case Rep J 2018;5:e73. [PMID: 30370312 DOI: 10.14309/crj.2018.73] [Reference Citation Analysis]
82 Nichols MM, Crane GM. Educational Case: Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies and Potential Role of the Spleen. Acad Pathol 2021;8:23742895211001312. [PMID: 33855171 DOI: 10.1177/23742895211001312] [Reference Citation Analysis]
83 Yang J, Wu Z, Xie X, Liu G, Fang Y, Wu J, Lin J. Characterization of the interactions of ADAMTS13 CUB1 domain to WT- and GOF-Spacer domain by molecular dynamics simulation. J Mol Graph Model 2021;109:108029. [PMID: 34517169 DOI: 10.1016/j.jmgm.2021.108029] [Reference Citation Analysis]
84 Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Res Pract Thromb Haemost 2019;3:26-37. [PMID: 30656273 DOI: 10.1002/rth2.12160] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
85 Smock KJ. ADAMTS13 testing update: Focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies. Int J Lab Hematol 2021;43 Suppl 1:103-8. [PMID: 34288437 DOI: 10.1111/ijlh.13557] [Reference Citation Analysis]
86 Graça NAG, Joly BS, Voorberg J, Vanhoorelbeke K, Béranger N, Veyradier A, Coppo P. TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol 2022. [PMID: 35146746 DOI: 10.1111/bjh.18040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Chen JK, Tang N, Wang X, Huang M, Zhang C. A Case of Parturient with Hereditary Thrombotic Thrombocytopenic Purpura: Case Report of a Novel Variant. Semin Thromb Hemost 2021. [PMID: 34388840 DOI: 10.1055/s-0041-1732466] [Reference Citation Analysis]
88 Mojiri A, Alavi P, Jahroudi N. Von Willebrand factor contribution to pathophysiology outside of von Willebrand disease. Microcirculation 2018;:e12510. [PMID: 30365187 DOI: 10.1111/micc.12510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
89 Yıldız S, Demirkan F. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies? Transfus Apher Sci 2018;57:31-4. [PMID: 29506907 DOI: 10.1016/j.transci.2018.02.013] [Reference Citation Analysis]
90 Maqsood MH, Rubab K, Maqsood MZ. Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Cureus 2019;11:e5263. [PMID: 31576256 DOI: 10.7759/cureus.5263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Zafrani L, Dekimpe C, Joly BS, Roose E, Fieux F, Azoulay E, Peraldi MN, Durrbach A, Coppo P, Vanhoorelbeke K, Veyradier A. Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation. Haematologica 2019;104:e277-80. [PMID: 30819908 DOI: 10.3324/haematol.2019.219063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Shaw RJ, Dutt T. Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura. Br J Haematol. [DOI: 10.1111/bjh.18127] [Reference Citation Analysis]
93 Pisklakova A, Barbir J, Sambataro JP, Almanzar C, Manji F. Silent Thrombotic Thrombocytopenic Purpura: PLASMIC, Lessons Learned, and Current Management Overview. Cureus 2021;13:e13803. [PMID: 33842174 DOI: 10.7759/cureus.13803] [Reference Citation Analysis]
94 Beranger N, Benghezal S, Joly BS, Capdenat S, Delton A, Stepanian A, Coppo P, Veyradier A. Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay. Res Pract Thromb Haemost 2021;5:81-93. [PMID: 33537532 DOI: 10.1002/rth2.12461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
95 Jolobe OMP. Extending the clinical spectrum of thrombotic thrombocytopenic syndrome attributable to adenovirus-based vaccines for Covid-19. Am J Emerg Med 2021:S0735-6757(21)00437-X. [PMID: 34059386 DOI: 10.1016/j.ajem.2021.05.053] [Reference Citation Analysis]
96 Noutsos T, Laidman AY, Survela L, Arvanitis D, Segalla R, Brown SG, Isbister GK. An evaluation of existing manual blood film schistocyte quantitation guidelines and a new proposed method. Pathology 2021:S0031-3025(21)00087-8. [PMID: 33863504 DOI: 10.1016/j.pathol.2021.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Dupuy H, Lazaro E, Machelart I, Viallard JF, Coppo P, Rivière E. Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open 2018;2:e407-10. [PMID: 31249968 DOI: 10.1055/s-0038-1676357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Boender J, Nederlof A, Meijer K, Mauser-Bunschoten EP, Cnossen MH, Fijnvandraat K, van der Bom JG, de Meris J, Laros-van Gorkom BAP, van Galen KPM, Eikenboom J, de Maat MPM, Leebeek FWG; WiN Study Group. ADAMTS-13 and bleeding phenotype in von Willebrand disease. Res Pract Thromb Haemost 2020;4:1331-9. [PMID: 33313472 DOI: 10.1002/rth2.12442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Lien LM, Lu WJ, Lin KH, Kang LH, Chen TY, Lin BJ, Lu YC, Huang CY, Shih CM, Chen H, Tsai YC, Chen RJ, Sheu JR. Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets. Molecules 2021;26:5340. [PMID: 34500771 DOI: 10.3390/molecules26175340] [Reference Citation Analysis]